Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)
Regeneron reported first clinical results for ubamatamab, its MUC16xCD3 bispecific antibody, in recurrent low-grade serous ovarian cancer at the IGCS 2026 meeting. Among 11 heavily pre-treated patients receiving 800 mg monotherapy, ubamatamab showed a 73% objective response rate and 11-month median progression-free survival — well above the sub-15% ORR typical of chemotherapy in this setting, and without biomarker selection. The company is enrolling a dedicated, potentially registrational LGSOC cohort of up to 100 patients at the 800 mg dose, will discuss the data with the FDA in the coming months, and plans a confirmatory randomized Phase 3 trial.
Key figures
- Drug Name
- ubamatamab (MUC16xCD3 bispecific antibody)
- Phase Of Trial
- Phase 1/2
- Orr
- 73% at 800 mg dose (95% CI: 39.0-94.0)
- Median pfs
- 11 months
- Crs incidence
- 90%, all Grade 1 or 2
- Grade3plus trae
- 21%
- Patients at 800mg
- 11
- Lgsoc subset patients
- 19
- Median duration of response
- 9 months
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.